Wall Street expects a year-over-year increase in earnings on higher revenues when Collegium Pharmaceutical (COLL) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy wit ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tri ...

Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 29:Ultrapar Participações S.A. (UGP) : This energy and infrastructure company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 31.8% over the last 60 days.Ultrapar Participações has a price-to-earnings ratio (P/E) of 19.66 compared with 22.57 for the S&P. The company possesses a Value Score of B.Honda Motor Co., Ltd. (HMC) : This autom ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET Company Participants Christopher James - VP of Investor Relations Joseph Ciaffoni - President and CEO Colleen Tupper - EVP and CFO Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Serge Belanger - Needham & Co. Leszek Sulewski - Truist Securities Oren Livnat - H.C. Wainwright Operator Greetings, and welcome to the Collegium Pharmaceutical Fourth Quarte ...

Life-Threatening Respiratory Depression Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of BELBUCA and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. See full prescribing information, including Boxed Warning on Addiction, Abuse and Misuse, and Other Serious Risks at ...

For the quarter ended December 2023, Collegium Pharmaceutical (COLL) reported revenue of $149.75 million, up 15.5% over the same period last year. EPS came in at $1.58, compared to $1.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $147.66 million, representing a surprise of +1.41%. The company delivered an EPS surprise of +18.80%, with the consensus EPS estimate being $1.33.While investors closely watch year-over-year changes in headline numbers -- revenue and ea ...

04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia 03-0416362 (State or other jurisdiction of inco ...